Background:

Basal cell carcinoma is the most frequent non-melanoma skin cancer, it is a tumor of local invasion and slow growth; it has its origin from the epidermal cells of the hair follicles or the basal cells of the epidermis; sometimes it can suffer uncontrolled growth, not respond to treatments and cause deformity; ultraviolet radiation is the main factor in the genesis of this disease.

Objective:

To describe the results of the application of HeberFERON in a series of cases with basal cell carcinoma of the face.

Methodology:

An observational, longitudinal descriptive study was carried out in a series of 32 clinical cases of basal cell carcinoma of the face that attended the dermatology office of the Polyclinic Center. Those with clinical, dermatoscopic and histopathological diagnosis were included. An initial evaluation was carried out, during the treatment and 16 weeks after it, 10.5 IU of HeberFERON was administered 3 times per week until 9 doses were completed. The variables were the response to treatment and the presence or absence of adverse events.

Results:

Male sex, white skin and the location of the neoplasm in the nose predominated; a complete response was achieved in most patients. Adverse events presented pain at the injection site, fever and malaise.

Conclusions:

The objective response to treatment was favorable in the majority of patients treated with HeberFERON.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )